outlook cut rx pharma
ep best con larg due one-tim tax save
consum busi larg line rx pharma continu
under-perform revenue ep guidanc cut respect new ceo
kessler share initi view envis transit co
narrow healthcar focu broader self care theme underscor
experi consum return bolt acquisit also appear
management cut guidanc persist weak gener rx busi global
health impact surpris number oper issu disclos rx
pharma rev declin y/i due lack new product price eros
certain author gener ag product management also call custom servic challeng
 oper effici inconsist suppli certain partner result lower
sale volum taken togeth increas adj oper margin fell
rx divis vs histor rang beyond result recent launch gener
androgel experienc intens competit ag also contribut
lower outlook chc-america rev grew exclud under-perform anim health
busi net sale anim declin due loss partner product
advers channel dynam importantli post organ revenue growth chc-
intern oper margin improv y/i reflect gross margin gain
oper leverag taken togeth management lower revenue ep guidanc
mid point respect take correct
action recruit sharon kochan led rx busi take
rein divis said number oper challeng management highlight
could take time resolv rise input cost tight labor market
new ceo share initi view expans consum segment
reinvigor growth mr kessler job month
alreadi strong view busi appear major
chang agent agre separ rx busi lead better corpor
align elimin compet prioriti said believ rx busi
healthi pipelin could turnaround quickli key approv
consum side view dearth new product chca key problem given
limit opportun rx over-the-counter switch huge driver growth past decad
underscor consum product background mr kessler see potenti vast new
opportun adjac consum categori envis becom key player
self care use prgo chci busi analog market number lifestyl
brand store brand plan share comprehens strateg plan
invest commun next spring evalu busi complet
clear bolt acquisit return central part overal strategi
strong balanc sheet offer dri powder invest new
share purchas author gener cash oper
net debt lever repurchas
stock board approv new share buy-back plan expir
deploy cash mr kessler champion invest organ growth asset
bolt-on improv critic mass eu technolog improv custom servic
us rather inorgan financi asset achiev low return co
review altern anim health busi mr kessler note adjac consum
categori like one make sens thought could potenti opportun
import success brands/product line chci busi importantli seem
oppos transform acquisit near term histor
valu enhanc sharehold
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
chart perrigo quarterli varianc analysi except per-shar data
page
pleas see import disclosur inform page report
changetot cost interest/oth incom ep fulli outstand fulli revenu changeconsum healthcar healthcar pharma
perrigo compani plc lead global healthcar supplier develop manufactur distribut over-the-count over-the-counter
prescript rx pharmaceut nutrit product activ pharmaceut ingredi api
price target base forward price-to-earnings multipl support dcf analysi risk includ gener price eros delay
new product launch sluggish chca chci growth
david steinberg certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
edward chung certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
anthoni baldor certifi view express research report accur reflect person view subject secur
subject compani also certifi part compens directli indirectli relat specif recommend
view express research report
case jefferi employe analyst respons coverag financi instrument discuss report receiv
compens base part overal perform firm includ invest bank incom seek updat research
appropri variou regul may prevent us asid certain industri report publish period basi larg major
report publish irregular interv appropri analyst judgement
articl articl
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within period
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate secur averag
secur price consist expect total return price appreci plu yield plu minu within period
under-perform rate secur averag secur price consist expect total return price appreci plu yield minu
less within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/
jefferi polici
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic secur regul
prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project opinion
invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil expect total
return next month price target base sever methodolog may includ restrict analys market
premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
page
pleas see import disclosur inform page report
jefferi franchis pick includ stock select among best stock idea equiti analyst month period stock select
base fundament analysi may take account factor analyst convict differenti analysi favor risk/reward
ratio invest theme jefferi analyst recommend jefferi franchis pick includ buy rate stock number
vari depend analyst recommend inclus stock ad new opportun aris remov reason
inclus chang stock met desir return longer rate buy and/or trigger stop loss stock day volatil
bottom quartil stock continu stop loss remaind stop franchis pick intend
repres recommend portfolio stock sector base may note believ pick fall within invest style
growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor financi
instrument discuss report may suitabl investor investor must make invest decis base upon
specif invest object financi situat util financi advisor deem necessari past perform financi
instrument recommend report taken indic guarante futur result price valu incom
financi instrument mention report rise well fall may affect chang econom financi polit
factor financi instrument denomin currenc investor home currenc chang exchang rate may advers affect
price valu incom deriv financi instrument describ report addit investor secur adr whose
valu affect currenc underli secur effect assum currenc risk
note box rate price target histori chart repres action past three year analyst initi
compani made chang rate price target compani discontinu coverag compani
import disclosur inform compani recommend report pleas visit websit http //javatar bluematrix com/sellside/
